Publications by authors named "J C Remy"
RNA interference is a widely used biological process by which double-stranded RNA induces sequence-specific gene silencing by targeting mRNA for degradation. However, the physicochemical properties of siRNAs make their delivery extremely challenging, thus limiting their bioavailability at the target site. In this context, we developed a versatile and selective siRNA delivery system of a trastuzumab-conjugated nanocarrier.
View Article and Find Full Text PDFArticle Synopsis
- A healthy ocean significantly contributes to human well-being by providing essential resources like medicines, food, and recreational opportunities, but its benefits are often overlooked.
- Climate change, pollution, loss of biodiversity, and social inequities pose serious threats to both ocean health and human health.
- To harness the ocean's health benefits sustainably, there must be a focus on equitable partnerships, enforcement of laws, and attention to human rights, social justice, and sustainability, with the healthcare sector playing a key role in this initiative.
Purpose: To evaluate the quality of lung perfusion imaging obtained with photon-counting-detector CT (PCD-CT) in comparison with dual-source, dual-energy CT (DECT).
Methods: Seventy-one consecutive patients scanned with PCD-CT were compared to a paired population scanned with dual-energy on a 3rd-generation DS-CT scanner using (a) for DS-CT (Group 1): collimation: 64 × 0.6 × 2 mm; pitch: 0.
Purpose: To compare the diagnostic approach of acute pulmonary embolism (PE) with photon-counting-detector CT (PCD-CT) and energy-integrating-detector CT (EID-CT).
Materials And Methods: Two cohorts underwent CT angiographic examinations with EID-CT (Group 1; n = 158) and PCD-CT (Group 2; n = 172), (b) with two options in Group 1, dual energy (Group 1a) or single energy (Group 1b) and a single option in Group 2 (spectral imaging with single source).
Results: In Group 2, all patients benefited from spectral imaging, only accessible to 105 patients (66.
Combined BRAF/MEK-inhibition constitutes a relevant treatment option for -mutated advanced melanoma. The prospective, non-interventional COMBI-r study assessed the effectiveness and tolerability of the BRAF-inhibitor dabrafenib combined with the MEK-inhibitor trametinib in patients with advanced melanoma under routine clinical conditions. Progression-free survival (PFS) was the primary objective, and secondary objectives included overall survival (OS), disease control rate, duration of therapy, and the frequency and severity of adverse events.
View Article and Find Full Text PDF